

Title (en)  
COMPOSITION INVOLVED IN REGULATING ENERGY CYCLE, INFLAMMATION AND INSULIN RESISTANCE DYSFUNCTIONS, AND USE THEREOF PARTICULARLY IN CARDIOMETABOLIC DISEASES

Title (de)  
ZUSAMMENSETZUNG ZUR REGULIERUNG VON ENERGIEZYKLUS-, ENTZÜNDUNGS- UND INSULINRESISTENZFUNKTIONSSTÖRUNGEN UND VERWENDUNG DAVON INSBESONDERE IN HERZ-KREISLAUF-ERKRANKUNGEN

Title (fr)  
COMPOSITION INTERVENANT DANS LA REGULATION DU DYSFONCTIONNEMENT DES CYCLES DE L'ENERGIE, DE L'INFLAMMATION ET DE L'INSULINORESISTANCE ET SON UTILISATION NOTAMMENT DANS LES MALADIES CARDIOMETABOLIQUES

Publication  
**EP 3046552 A1 20160727 (FR)**

Application  
**EP 14744782 A 20140702**

Priority  
• FR 1356444 A 20130702  
• FR 1356446 A 20130702  
• FR 1356448 A 20130702  
• FR 1356450 A 20130702  
• EP 2014064110 W 20140702

Abstract (en)  
[origin: WO2015000986A1] The invention relates to a composition suitable for use as a health product, comprising a mixture of active ingredients made up of at least: - a lactoserum hydrolysate with a molecular weight comprised between 200 and 5000 daltons, - alpha-lactalbumin, - at least one AMPK, MAPK, PPAR and/or SIRT1 cycle regulator, - milk calcium. It is particularly useful as a medical nutrition product or orally administered drug, to prevent and/or combat various diseases.

IPC 8 full level  
**A23L 33/00** (2016.01); **A61K 31/155** (2006.01); **A61K 31/366** (2006.01); **A61K 31/4415** (2006.01); **A61K 31/7016** (2006.01); **A61K 33/00** (2006.01); **A61K 33/06** (2006.01); **A61K 35/20** (2006.01); **A61K 38/01** (2006.01); **A61K 38/08** (2019.01); **A61K 38/38** (2006.01); **A61P 3/00** (2006.01); **A61P 3/04** (2006.01)

CPC (source: EP US)  
**A23L 33/15** (2016.07 - EP US); **A23L 33/155** (2016.07 - EP US); **A23L 33/16** (2016.07 - EP US); **A23L 33/175** (2016.07 - EP US); **A23L 33/18** (2016.07 - EP US); **A23L 33/19** (2016.07 - EP US); **A61K 9/0053** (2013.01 - US); **A61K 31/155** (2013.01 - US); **A61K 31/198** (2013.01 - EP US); **A61K 31/202** (2013.01 - US); **A61K 31/355** (2013.01 - EP US); **A61K 31/366** (2013.01 - EP US); **A61K 31/401** (2013.01 - US); **A61K 31/405** (2013.01 - US); **A61K 31/426** (2013.01 - EP US); **A61K 31/4375** (2013.01 - US); **A61K 31/4415** (2013.01 - EP US); **A61K 31/59** (2013.01 - US); **A61K 33/04** (2013.01 - US); **A61K 33/06** (2013.01 - EP US); **A61K 33/30** (2013.01 - US); **A61K 35/20** (2013.01 - EP US); **A61K 38/06** (2013.01 - EP US); **A61K 38/08** (2013.01 - EP US); **A61K 38/193** (2013.01 - EP US); **A61K 38/38** (2013.01 - EP US); **A61K 38/446** (2013.01 - EP US); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A23V 2002/00** (2013.01 - EP US); **A61K 2300/00** (2013.01 - EP US); **C12Y 115/01001** (2013.01 - EP US)

Citation (search report)  
See references of WO 2015000986A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2015000986 A1 20150108**; EP 3046552 A1 20160727; US 2016375061 A1 20161229

DOCDB simple family (application)  
**EP 2014064110 W 20140702**; EP 14744782 A 20140702; US 201414902518 A 20140702